Lexeo Therapeutics, Inc. announced it has entered into a common stock purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 6,278,905 shares of its common stock at an issue price of $15.13 per share for gross proceeds of $95,000,000 on March 11, 2024. the transaction will include participation from Braidwell LP, Adage Capital Partners LP, RA Capital Management, Surveyor Capital, Eventide Asset Management and Novo Holdings A/S. The transaction is expected to close on March 13, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.86 USD | +0.11% | +3.36% | +4.43% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.43% | 456M | |
+40.41% | 50.93B | |
-0.44% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+13.04% | 26.02B | |
-22.19% | 18.9B | |
+8.18% | 13.21B | |
+24.20% | 12.17B | |
+30.63% | 12.16B |
- Stock Market
- Equities
- LXEO Stock
- News Lexeo Therapeutics, Inc.
- Lexeo Therapeutics, Inc. announced that it expects to receive $94.999833 million in funding